NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company, unwavering in its mission to develop and commercialize technologies for central nervous system (CNS) therapeutics, principally brain cancer, that address the persistent challenges in overcoming the blood-brain barrier.
Latest News and Insights
NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results
NeOnc Provides Business Update and Reports Q4 2025 Financial Results
NeOnc Technologies Appoints David Choi as Chief Accounting Officer
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity
NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management
Minimum 15 minutes delayed. Source: LSEG
Stock Information
Investing in the Future of CNS Therapeutics
Our commitment to advancing brain and central nervous system therapeutics drives our mission to create enduring value for patients and stakeholders alike. We believe our relentless pursuit of innovative solutions to transform the standard of care is a catalyst for long-term growth. Through a focused dedication to research, strategic collaboration with leading medical professionals, and a patient-centric approach, we are positioned to deliver impactful treatments and robust returns. Our groundbreaking work is not only about bringing hope and extending lives, it’s about building a sustainable and valuable enterprise for the future.
Your Essential Financial Records
SEC Filings & Financial Disclosures
At NeOnc, we’re committed to providing our investors with comprehensive, timely access to our financial information. This dedicated section serves as your central hub for all regulatory reports and financial data. Here, you’ll find our complete collection of SEC filings, including crucial documents like our quarterly 10-Q statements, and timely 8-K disclosures for significant events. These filings, along with other financial disclosures, offer a detailed and reliable look into our company’s performance, operational health, governance practices, and strategic direction, empowering you to make informed investment decisions.
Amir Heshmatpour
Thomas Chen, MD, PhD
Keithly A. Garnett
David M. Ashley, MBBS (Hons), FRACP, PhD, Duke University
Josh Neman, PhD
Alan Chiang, MD, PhD, MBA, FICS
Bader Almonawer
Henry S. Friedman, MD, Duke University
Steven L. Giannotta, MD
Jim Delshad
Alexandra M. Miller, MD, PhD, NYU Langone Health
Axel H. Schönthal, PhD
Victoria Medvec, PhD